Human immunity against EBV-lessons from the clinic.

Area of Science:

• Immunology
• Virology
• Genetics

Background:

• Epstein-Barr virus (EBV) infects over 90% of individuals, typically remaining latent.
• EBV can cause severe, fatal diseases, especially in immunocompromised individuals, including those with primary immunodeficiencies (PIDs).
• PIDs offer crucial insights into the immune system's defense against EBV.

Purpose of the Study:

• To review the virology of EBV.
• To explore disease pathogenesis in PIDs related to EBV.
• To discuss advancements in immune cell-mediated therapies for EBV-associated disorders.

Main Methods:

• Literature review of EBV virology.
• Analysis of disease mechanisms in primary immunodeficiencies.
• Examination of current immune cell-based therapeutic strategies.

Main Results:

• EBV has evolved sophisticated mechanisms to maintain host survival and latency.
• Specific PIDs highlight essential cellular and molecular components for controlling EBV.
• Understanding these deficiencies aids in developing targeted treatments.

Conclusions:

• Robust immunity is crucial for lifelong control of EBV.
• PIDs serve as models for dissecting immune responses to EBV.
• Immune cell-mediated therapies show promise for treating severe EBV-related conditions.